Johnson & Johnson and BioMarin Pharmaceutical Inc.: SG&A Spending Patterns Compared

SG&A Spending: Johnson & Johnson vs. BioMarin

__timestamp	BioMarin Pharmaceutical Inc.	Johnson & Johnson
Wednesday, January 1, 2014	302156000	21954000000
Thursday, January 1, 2015	402271000	21203000000
Friday, January 1, 2016	476593000	19945000000
Sunday, January 1, 2017	554336000	21420000000
Monday, January 1, 2018	604353000	22540000000
Tuesday, January 1, 2019	680924000	22178000000
Wednesday, January 1, 2020	737669000	22084000000
Friday, January 1, 2021	759375000	20118000000
Saturday, January 1, 2022	854009000	19046000000
Sunday, January 1, 2023	937300000	20112000000
Monday, January 1, 2024	1009025000	21969000000

Unveiling the hidden dimensions of data

SG&A Spending Patterns: A Tale of Two Giants

In the world of pharmaceuticals, understanding spending patterns can reveal much about a company's strategic priorities. Over the past decade, Johnson & Johnson and BioMarin Pharmaceutical Inc. have showcased contrasting approaches in their Selling, General, and Administrative (SG&A) expenses.

From 2014 to 2023, Johnson & Johnson consistently allocated a significant portion of its budget to SG&A, with expenses peaking at approximately $22 billion in 2018. This reflects a robust commitment to maintaining its market presence and operational efficiency. In contrast, BioMarin's SG&A expenses, while much smaller, have shown a steady increase, growing by over 200% from 2014 to 2023. This suggests a strategic expansion and investment in growth initiatives.

These spending patterns highlight the different scales and strategies of these industry leaders, offering insights into their operational priorities and market positioning.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025